Table 1 Basic clinical characteristics of the patients undergoing CT-guided transthoracic core-needle biopsy
Variable | Fusion imaging group (N = 76) | Routine group (N = 69) | P value | |
|---|---|---|---|---|
Age(year) | Mean ± SD | 65.1 ± 11.1 | 60.8 ± 12.6 | 0.031 |
Gender | Male/female | 55/21 | 44/25 | 0.266 |
Smoking status | Ex- or current/never | 10/24/42 | 26/11/32 | 0.002 |
Cancer history | Pulmonary/extra-pulmonary/no | 0/9/67 | 0/3/66 | 0.102 |
Previous thoracic operation | Yes/no | 2/74 | 4/65 | 0.339 |
Use of antiplatelet or anticoagulative drugs (e.g. aspirin, clopidogrel, warfarin, low molecular weight heparin, etc.) | Yes/no | 14/62 | 17/52 | 0.362 |
Emphysema (on CT scan) | Yes/no | 14/62 | 18/51 | 0.266 |
Location of consolidation or mass | Right/left/bilateral | 42/29/5 | 33/33/3 | 0.472 |
Lobar involvement of consolidation or mass | < 1/2lobe/ > 1/2lobe/ > lobe | 54/16/6 | 49/17/3 | 0.626 |
Lesion size (short diameter, cm) | Mean ± SD | 5.18 ± 2.19 | 5.08 ± 1.88 | 0.770 |
Position for biopsy procedure | Supine/prone | 48/28 | 44/25 | 0.939 |
Procedure duration (min) | Mean ± SD | 8.7 ± 2.4 | 9.4 ± 3.4 | 0.198 |
The interval between PET/CT and CT (day) | Median ± IQR | 5 ± 10 | – | |
Mean SUVmax value | Median ± IQR | 8.0 ± 6.0 | – | |
18F-FDG uptake pattern | Uniform higher uptake/focal uptake/without uptake | 29/46/1 | – | |
Operation/ follow-up* | 23/53 | 16/53 | 0.337 | |
The length of follow-up (month) | Median ± IQR | 11 ± 7 | 10 ± 8 | 0.735 |
Complications | Pneumothorax/ intrapulmonary hemorrhage /hemoptysis | 18/14/6 | 21/10/4 | 0.555 |
Note: SD, standard deviation; IQR, interquartile range; SUV, standardized uptake value | ||||